ArticleGynecologic oncology reports2025
Landscape of genomic alterations and clinical outcomes in low-grade serous ovarian cancer in Korea.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the somatic mutational landscape of ovarian cancer in Estonia.Acta oncologica (Stockholm, Sweden) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To investigate the clinical characteristics, molecular findings, and survival outcomes of patients with low-grade serous ovarian cancer in Korea, with a focus on addressing the limited data on genetic profiling and targeted therapies in Asian populations. Methods: This study is a retrospective review of patients with pathologically confirmed LGSOC treated at the National Cancer Center Korea between 2010 and 2023. Patients underwent cytoreductive surgery and/or systemic or hormonal therapy. Molecular profiling included next-generation sequencing (NGS) of formalin-fixed, paraffin-embedded tumor samples and homologous recombination deficiency (HRD) testing. Survival outcomes were assessed using Kaplan-Meier analysis. Results: A total of 62 patients were included, with a median age of 41 years; 61.3 % presented with advanced-stage disease. BRCA mutations were detected in 6.4 % ( Conclusion: This study identifies frequent MAPK pathway mutations, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.